article thumbnail

SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]

Annals of Family Medicine

Context Two thirds of diabetes patients complicated with hypertension, and comorbidity increase 4-fold risk of atherosclerotic cardiovascular disease (ASCVD). Population Studied individuals with comorbidity of hypertension and type 2 diabetes. Outcome Measures Changes of China-PAR score and cardiovascular hospitalization events.

article thumbnail

Key Facts GPs Should Know About GLP-1 Analogs

Family Medicine Initiative

So, which patients should get them first? Patients ask me these questions fairly often, so I know it’s important for GPs to know the key facts. Yes, one year after stopping the medication, patients regain ½ – ⅔ of their previous weight loss: What are other clinical benefits? What are the true benefits and side effects?

Diabetes 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diabetes drugs associated with fewer adverse cardiac events in older veterans

Medical Xpress

GLP1 receptor agonists—a class of diabetes medications—are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.

article thumbnail

Revisiting the Advantages of aSOAP Notes: The Best of the Paper Chart and Old School Photography

A Country Doctor Writes

We may only have 15 minutes with each patient. In primary care it is often necessary to think in terms of including more than our area of interest in our mental picture of our patient. My system lets me choose whether to import everything or essentially nothing from the patient’s past medical history.

article thumbnail

What to Expect at the ADA 85th Scientific Sessions: Obesity, Nutrition, Prevention, and More

Physician's Weekly

The ADA’s 85th Scientific Sessions will highlight breakthroughs in obesity and diabetes care, including GLP-1 therapies, tech advances, and prevention tools. The event will convene more than 11,000 global researchers, clinicians, and industry leaders to highlight major strides in research and real-world treatment. Roughly 42% (109.9

article thumbnail

FDA Approves Polypill Widaplik for Hypertension

Physician's Weekly

The combination pill is the first and only FDA-approved triple combination medication for use as an initial therapy in patients who will likely need multiple drugs to achieve their ideal blood pressure numbers. The most common adverse event reported in patients treated with Widaplik was symptomatic low blood pressure.

article thumbnail

Why Identifying and Managing Giant Cell Arteritis as an Emergency Is Crucial

Physician's Weekly

Leonard Calabrese, DO, Paras Karmacharya, MD, MS, and Adam Kilian, MD, break down why giant cell arteritis (GCA) demands immediate action, explain how to confirm diagnosis quickly, and what same-day treatment options like upadacitinib (Rinvoq) mean for patient care. Video Transcript: Hi, this is Dr. Len Calabrese.